Neoantigen
Targeted Therapies Market is estimated to be worth USD 3 Billion in 2030,
predicts Roots Analysis
Advances
in bioinformatics and genomic data analysis have enabled the identification of
cancer antigens that are generally overlooked during immune surveillance; these
neoantigens have been shown to possess substantial therapeutic potential
